Abstract
BackgroundCemiplimab (Libtayo®), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor, is approved for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC), who are...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have